▲ 2.20%
prev close
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Congressional Trades
13
All tracked trades
Members Trading
8
Unique members
Net Activity
+5
9 buys · 4 sells
Members Who Traded This Stock
13 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-05-06 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 123d ago | — | |
| 2026-05-06 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 123d ago | — | |
| 2026-01-27 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 236d ago | — | |
| 2025-09-23 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 375d ago | — | |
| 2025-05-05 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 532d ago | — | |
| 2025-04-16 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 524d ago | — | |
| 2025-03-10 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 557d ago | — | |
| 2025-03-07 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 558d ago | — | |
| 2024-10-29 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 403d ago | — | |
| 2023-09-26 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 1076d ago | — | |
| 2023-07-12 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1164d ago | — | |
| 2023-03-06 | GILDGilead Sciences Inc | Buy | $15,001 - $50,000 | 1282d ago | — | |
| 2021-11-10 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1509d ago | — |
2026-05-06
Jared Moskowitz
GILD
Amount
$1,001 - $15,000
Filed
123d ago
2026-05-06
Jared Moskowitz
GILD
Amount
$1,001 - $15,000
Filed
123d ago
2026-01-27
Josh Gottheimer
GILD
Amount
$1,001 - $15,000
Filed
236d ago
2025-09-23
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
375d ago
2025-05-05
Marjorie Taylor Greene
GILD
Amount
$1,001 - $15,000
Filed
532d ago
2025-04-16
John Boozman
GILD
Amount
$1,001 - $15,000
Filed
524d ago
2025-03-10
Carol Devine Miller
GILD
Amount
$1,001 - $15,000
Filed
557d ago
2025-03-07
Josh Gottheimer
GILD
Amount
$1,001 - $15,000
Filed
558d ago
2024-10-29
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
403d ago
2023-09-26
Greg Stanton
GILD
Amount
$1,001 - $15,000
Filed
1076d ago
2023-07-12
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1164d ago
2023-03-06
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1282d ago
2021-11-10
Carol Devine Miller
GILD
Amount
$15,001 - $50,000
Filed
1509d ago
Recent News
Powered by Polygon.io
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Trade Timeline
Congressional activity, newest first
Jared Moskowitz
2026-05-06 · Purchase
$1,001 - $15,000
Jared Moskowitz
2026-05-06 · Purchase
$1,001 - $15,000
Josh Gottheimer
2026-01-27 · Purchase
$1,001 - $15,000
Valerie Hoyle
2025-09-23 · Sale
$1,001 - $15,000
Marjorie Taylor Greene
2025-05-05 · Purchase
$1,001 - $15,000
John Boozman
2025-04-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2025-03-10 · Purchase
$1,001 - $15,000
Josh Gottheimer
2025-03-07 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000